Insider Buying: Enovis (NYSE:ENOV) Insider Acquires $23,000.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,000 shares of the stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average cost of $23.00 per share, with a total value of $23,000.00. Following the completion of the transaction, the insider owned 50,640 shares in the company, valued at approximately $1,164,720. This represents a 2.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Monday, June 1st, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were acquired at an average cost of $22.22 per share, with a total value of $22,220.00.
• On Friday, March 13th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.74 per share, with a total value of $23,740.00.

Enovis Trading Up 2.7%

NYSE:ENOV opened at $21.70 on Friday. The stock has a 50-day simple moving average of $24.03 and a 200-day simple moving average of $24.60. The stock has a market cap of $1.25 billion, a P/E ratio of -1.09 and a beta of 1.38. Enovis Corporation has a 1 year low of $20.55 and a 1 year high of $36.82. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP acquired a new stake in Enovis during the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY lifted its position in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the period. AQR Capital Management LLC lifted its position in Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after acquiring an additional 434,646 shares during the period. Front Street Capital Management Inc. lifted its position in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP lifted its position in Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ENOV has been the subject of a number of research analyst reports. Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. Zacks Research cut Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Needham & Company LLC upped their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.